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Mutations in SLC33A1 Cause a Lethal Autosomal-Recessive
Disorder with Congenital Cataracts, Hearing Loss,
and Low Serum Copper and Ceruloplasmin
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Peter Freisinger,4 John Christodoulou,5 Merle Hillebrand,1 Gaele Pitelet,6 Callum Wilson,7
Ursula Gruber-Sedlmayr,8 Reinhard Ullmann,2 Stefan Haas,9 Orly Elpeleg,10 Gudrun Nu¨rnberg,11
Peter Nu¨rnberg,11 Shzeena Dad,12 Lisbeth Birk Møller,12 Stephen G. Kaler,13 and Jutta Ga¨rtner1
Low copper and ceruloplasmin in serum are the diagnostic hallmarks for Menkes disease, Wilson disease, and aceruloplasminemia. We
report on five patients from four unrelated families with these biochemical findings who presented with a lethal autosomal-recessive
syndrome of congenital cataracts, hearing loss, and severe developmental delay. Cerebral MRI showed pronounced cerebellar hypoplasia
and hypomyelination. Homozygosity mapping was performed and displayed a region of commonality among three families at chromo-
some 3q25. Deep sequencing and conventional sequencing disclosed homozygous or compound heterozygousmutations for all affected
subjects in SLC33A1 encoding a highly conserved acetylCoA transporter (AT-1) required for acetylation of multiple gangliosides and
glycoproteins. The mutations were found to cause reduced or absent AT-1 expression and abnormal intracellular localization of the
protein. We also showed that AT-1 knockdown in HepG2 cells leads to reduced ceruloplasmin secretion, indicating that the low copper
in serum is due to reduced ceruloplasmin levels and is not a sign of copper deficiency. The severity of the phenotype implies an essential
role of AT-1 in proper posttranslational modification of numerous proteins, without which normal lens and brain development is
interrupted. Furthermore, AT-1 defects are a new and important differential diagnosis in patients with low copper and ceruloplasmin
in serum.Introduction
Copper is an essential metal that facilitates electron
transfer reactions and is incorporated in many cuproen-
zymes that are involved in mitochondrial respiration,
antioxidant defense, connective tissue formation, neuro-
transmitter and melanin biosynthesis, and peptide
amidation.1 Excess amounts of copper, however, are toxic
because they facilitate the production of reactive oxygen
species. Because of a tightly controlled copper homeostasis,
intracellular free copper is limited to less than one free
copper ion per cell.2 After absorption in the duodenum,
copper is rapidly removed from the portal circulation by
the liver, the central organ in copper homeostasis, where
it is incorporated in cuproenzymes, distributed to the
general circulation, or secreted into bile (the major mecha-
nism for copper elimination).1
The human disorders of copper metabolism with a
known molecular defect are Wilson disease (MIM
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copper and ceruloplasmin are the diagnostic hallmarks.
However, only one disorder, Menkes disease, is caused by
copper deficiency. Defects of ATP7A, a Cu1þ-transporting
ATPase expressed in extrahepatic tissues, lead to excessive
intestinal copper accumulation and severe systemic copper
deficiency.6–8 In Wilson disease and aceruloplasminemia,
body copper levels are not reduced; on the contrary, in
Wilson disease they are increased because of reduced
excretion of copper in the bile. In these disorders the low
copper in plasma is a result of low or absent ceruloplasmin,
the carrier of 95% of the plasma copper.
In 2005, Horvath et al. described a patient with low
serum copper and ceruloplasmin with a phenotype unlike
Wilson and Menkes disease or aceruloplasminemia.9 The
syndrome was considered to represent a possible novel
defect in human copper metabolism, and several known
copper transport genes were evaluated and excluded as
underlying causes. We encountered four additional
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biochemical phenotype closely similar to that reported by
Horvath et al. We sought to identify the primary genetic
defect for this unique clinical and biochemical disease
entity.Subjects and Methods
Five patients from four families were included in the study. All legal
representatives gave written informed consent to the study and
the study was approved by the local institutional review boards.
Clinical features of patient 4 have already been published.9
Homozygosity Mapping
Genome-wide linkage analysis was performed with the Affymetrix
GeneChip Human Mapping 250K Nsp Array. Data handling,
evaluation, and statistical analysis was performed as described
previously.10
Deep Sequencing
Prior to deep sequencing, patient DNAs from the homozygous
interval were enriched by means of a Sure Select Capture Array
according to the manufacturer’s protocols (Agilent, Santa Clara,
CA). The custom-designed array comprised 242,393 probes
representing 1,623 exons mapping to the genomic interval chr3:
153423761–166861604, hg19 with a 3 bp tiling and a 69 bp exten-
sion on each side. Repetitive sequences were not masked.
Single-end deep sequencing was performed on the Solexa
Genome Analyzer GAIIx. Read length was 76 nt. Sequences were
analyzed with in-house-developed tools.
Mutation Analysis by Sanger Sequencing
Total genomic DNA was prepared from peripheral blood samples
according to standard procedures.11 The six exons including
intron-exon boundaries of SLC33A1 (Genbank accession
NG_023365.1) were analyzed by direct sequencing on an ABI
377 semiautomated sequencer via the DNA Dye Terminator
Cycle Sequencing Kit (Applied Biosystems, Darmstadt, Germany)
according to the manufacturer’s instructions.
Construction of Eukaryotic Expression Vectors
Expression vectors, encoding wild-type human SLC33A1 and
mutated SLC33A1, were constructed as follows. Full-length wild-
type SLC33A1 cDNA was amplified via PCR with cDNA generated
from wild-type human fibroblasts and oligonucleotides con-
taining restriction enzyme sites (SLC33A1 cDNAFLAG forward,
50-atagtcgacatgtcacccaccatctccc-30; SLC33A1 cDNAFLAG rev,
50-ataggatccttaattgttccttttgcatttcc-30; SLC33A1 cDNA-EGFP-N1
forward, 50-atactcgagatgtcacccaccatctccc-30; SLC33A1 cDNA-
EGFP-N1 rev, 50-ataggatccaaattgttccttttgcatttcc-30). SLC33A1
mutants were generated by site-directed mutagenesis PCR with
the vector containing wild-type SLC33A1 cDNA as template
(SLC33A1 328G>C forward, 50-gctatacagaccaacctttcttcagttttg-30;
SLC33A1 328G>C rev, 50-caaaactgaagaaaggttggtctgtatagc-30;
SLC33A1 1098C>G forward, 50-gattatcagcaaatagactgcaggtccccag-30;
SLC33A1 1098C>G reverse, 50-ctggggacctgcagtctatttgctgataatc-30).
Synthesized wild-type andmutant cDNAs were cloned into the eu-
karyotic expression vector p3xFLAG-CMV 7.1 (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) pEGFP-N1 (Clontech Labo-
ratories, Inc., Mountain View, CA, USA). All constructs were veri-
fied by Sanger sequencing.62 The American Journal of Human Genetics 90, 61–68, January 13, 2Antibodies
Commercially available antibodies were used for the detection of
Protein Disulfide Isomerase (PDI; rabbit polyclonal antibody;
Sigma-Aldrich Chemie GmbH), Giantin (rabbit polyclonal anti-
body; Covance, Emeryville, CA, USA), Syntaxin 6 (rabbit mono-
clonal antibody [C34B2]; Cell Signaling Technology, Danvers,
MA, USA), Ceruloplasmin (mouse monoclonal [3B11]; Abcam,
Cambridge, UK), Albumin (mouse monoclonal anti-human
Albumin Clone HSA-11, Sigma, Saint Louis, MO, USA), and
GAPDH (mouse monoclonal [6C5] to GAPDH; Abcam). Recombi-
nant proteins were detected with mouse monoclonal anti-FLAG
M2 antibody (for western blot: Stratagene GmbH, La Jolla, CA,
USA; for immunofluorescence: SIGMA-Aldrich, Taufkirchen,
Germany) or mouse monoclonal anti-GFP antibody (JL9, Cell
Signaling Technology). As secondary antibodies for immunofluo-
rescent staining, goat anti-mouse IgG Cy3 and anti-rabbit IgG
Cy3 (Jackson Immuno-Research Laboratories, West Grove, PA,
USA) and Alexa Fluor 488 goat anti-rabbit IgG and anti-mouse
IgG (Molecular Probes Inc., Eugene, OR, USA) were used.
Minigene Construct
Genomic DNA fragments containing SLC33A1 wild-type
(c.12671G) and mutant (c.12671A) exon 5 along with 260 bp
of 50 and 274 bp of 30 intronic flanking sequences, were amplified
by PCR and cloned into the EcoRI and BamHI sites of the exon
trapping vector pSPL3 (GIBCO BRL). After the verification of the
minigene constructs by sequencing, HeLa cells were transiently
transfected each with both constructs. After 24 hr, total RNA
was extracted, reverse transcribed, amplified, and sequenced.
Oligonucleotides used for minigene construction, amplification,
and sequencing are listed in Table S1 available online.
Quantitative Real-Time PCR
First-strand cDNAs for qRT-PCR of RNA generated from patient
and control fibroblasts were synthesized as described above.
Quantitative RT-PCR was performed with the iQ5 cycler (BioRad
Laboratories) and the iQ SYBR Green Supermix kit (BioRad
Laboratories). All qRT-PCR reactions were performed in triplicate.
Annealing temperatures for the genes were set to 57C. Primer
sequences (GAPDH, SLC33A1) are listed in Table S1. Reaction
specificity was controlled by postamplification melting curve
analysis. Relative expression rates of target gene transcripts were
calculated with the 2(DDCt).Results
Five patients were included in the study. Four were from
consanguineous families. Patients 1 and 2 were siblings
originating from Tunisia, patient 3 was from Turkey,
patient 4 was from Saudi Arabia, and patient 5 was from
New Zealand. A summary of the genetic, laboratory, and
clinical data is given in Table 1 and the family pedigrees
are presented in Figure 1. All five patients presented with
a complex but similar phenotype. Severe psychomotor
retardation was present in all of them. None of the patients
was able to sit or walk independently and none learned to
speak. Less frequent were nystagmus (n ¼ 3) and seizures
(n ¼ 2). All patients died prematurely between ages
22 months and 6 years. Causes of death included pneu-
monia (n ¼ 2), kidney failure (n ¼ 1), and multiorgan012
Table 1. Phenotype and Genotype of the Patients with SLC33A1 Mutations
Patient 1 2 3 4 5
Sex M F M M M
Parental consanguinity yes yes yes yes no
Ancestry Tunisia Tunisia Turkey Saudi Arabia New Zealand
Mutation: DNA level c.12671G>A c.12671G>A c.1098C>G c.328G>C c.615_616insT,
c.1474_c.1482þ9del
Mutation: protein level p.Tyr366* p.Ala110Pro p.Leu205Phefs*31
Ceruloplasmin in plasma mg/l (200–600) nd <50 20–30 91–95 <20
Copper in plasma mg/dl (70–150) nd 17.5 <10 36–68 19
64Cu uptake in fibroblasts (8.2–30.8 ng) nd nd 56.7 41.3 54.8
Age at death (months) 72 22 42 48 22
Congenital cataracts þ þ þ þ þ
Nystagmus þ - þ þ -
Hearing loss þ þ þ þ þ
Developmental delay þ þ þ þ þ
Cerebellar atrophy þ þ þ þ þ
Cerebral atrophy þ þ þ þ þ
Hypomyelination þ þ þ þ þ
Normal values for copper and ceruloplasmin are given in brackets. Abbreviations: nd, not done; M, male; F, female.failure (n ¼ 1). In one case the cause of death is unknown.
Magnetic resonance imaging (MRI) of the brain showed
a uniform pattern with cerebellar hypoplasia, wide
subarachnoid spaces, and hypomyelination (Figure 2).
Serum copper was low (10%–20% of the low normal
rage) and ceruloplasmin very low or undetectable in four
patients. In patient 1, brother of patient 2, biochemical
evaluation was not done and the patient died before the
diagnosis was made. Copper levels in urine were normal
(n ¼ 3), as were levels in CSF (n ¼ 2) and in liver (n ¼ 1).
Three patients were treated with copper orally or subcuta-
neously. In the patient described by Horvath et al.,9 copper
treatment was reported to have had beneficial effects
but he nevertheless died at age 4 years. In all three of the
treated subjects, serum copper and ceruloplasmin levels
remained low.
By using the SNP array genotype data of four patients
(patients 1, 2, 3, and 4) from three consanguineous
families, we observed a single significant genome-wide
linkage peak on chromosome 3q25 with a maximum
multipoint LOD score of 4.51 (Figure S1). The underlying
common homozygous region between the SNP markers
rs9823065 and rs7646008 defined a candidate region of
13.4 Mb (neucleotides 153423761–166861604, hg19).
Array-based sequence capture of this region, followed by
next-generation sequencing in patients 2 and 4, showed
two homozygous mutations affecting the same gene,
SLC33A1, coding for themembrane acetyl-CoA transporter
(AT-1).12 A mutation search in the SLC33A1 gene per-
formed in the remaining patients by conventional SangerThe Amsequencing showed mutations in all (Figure 3). In patients
1 and 2, siblings from a consanguineous Tunisian family,
a homozygous mutation of the acceptor splice site of
exon 5, c.12671G>A, leading to partial or complete loss
of exon 5 was identified (Figure S2). In patient 3, a boy
from a consanguineous Turkish family, a homozygous
nonsense mutation c.1098C>G (p.Tyr366*) was detected
that causes a premature stop after 366 amino acids
(Figure S3). In patient 4, described earlier by Horvath
et al.,9 sequencing of the SLC33A1 gene revealed a homozy-
gous missense mutation c.328G>C (p.Ala110Pro) that was
not present in 122 unrelated control individuals. The
mutation introduces a proline instead of the highly
conserved alanine at position 110 of the polypeptide
(Figure S4). Topological prediction of mutant AT-1 with
the SOSUI program predicts that the mutation causes
a structural change in the first and second transmembrane
domain. The fifth patient, the only child in the cohort
from a nonconsanguineous family, was found to be
compound heterozygous for the c.615_616insT mutation
(p.Leu205Phefs*31) leading to a frame shift with a prema-
ture stop codon after 31 amino acids and the deletion
c.1474_c.1482þ9del leading to the loss of three amino
acid residues and 9 bp in intron 5 including the donor
splice site. DNA from the parents of patients 3 and 5 was
available and showed that they were heterozygous for
the mutations (Figure S3).
To assess the functional consequences of the mutations,
we performed quantitative real-time PCR in fibroblasts
from patients 3, 4, and 5 (Figure 4). Compared to normalerican Journal of Human Genetics 90, 61–68, January 13, 2012 63
Figure 1. Family Pedigrees
(A) Patients 1 and 2; (B) patient 3; (C) patient 4; (D) patient 5.
Figure 2. Cranial MRI Images
Patient 3 at age 36 months (A, B) and patient 5 at age 14 months
(C, D). Sagittal T1 images (A, C) demonstrate cerebellar hypoplasia
(white arrows); transversal T2 images (B, D) show wide subarach-
noid spaces (black arrows) and hypomyelination (*).control cells, the relative expression of SLC33A1 remains
unaltered by the missense mutation p.Ala110Pro whereas
the SLC33A1 mRNA level decreased 20% in fibroblasts of
patient 5 carrying a compound heterozygous mutation.
As a result of the nonsense mutation p.Tyr366*, we
observed a significantly reduced relative expression of
SLC33A1 in fibroblasts of patient 3, most probably because
of the quality-control function nonsense-mediated mRNA
decay.
Next we investigated the intracellular localization and
protein expression of endogenous AT-1 in patient fibro-
blasts by using immunocytochemical staining and western
blot analysis. After unsuccessful experiments with com-
mercially available AT-1-specific antibodies (data not
shown), we generated different vectors expressing
N terminally FLAG-tagged AT-1 fusion proteins. Western
blot analysis of lysates from transiently transfected
MCF-7 cells showed that the expressed fusion proteins
FLAG-AT-1 wild-type and FLAG-AT-1 p.Ala110Pro were
detected at the expected size of 62 kDa. In lysates of cells
transiently transfected with the construct carrying the
p.Tyr366* mutation, the full-length protein is missing
but we detected a shortened protein of around 43 kDa.
The above described expression vectors were then used
to analyze the intracellular localization of AT-1 in MCF-7
(Figure 4), HeLa, and CHO (data not shown). Contrary to
previous work, where AT-1 was described as restricted to64 The American Journal of Human Genetics 90, 61–68, January 13, 2the ER membrane, immunocytochemistry with a specific
FLAG antibody showed that the wild-type AT-1 protein
displayed a perinuclear cytoplasmic distribution and
colocalizes with marker proteins of the cis-, medial-, and
trans-Golgi. To exclude that the localization was a specific
effect of the FLAG-tag, we repeated the experiment
with a GFP-tag but obtained a similar result (Figure S5).
The missense mutation p.Ala110Pro produced a punctate
staining pattern in the cytoplasm that failed to colocalize
with the Golgi marker, and the nonsense mutant protein
p.Tyr366* was found to be distributed in the cytoplasm
where it strongly colocalized with the ER marker protein
PDI (Figure 4).
An intriguing finding in all the patients described in
this article was that copper and ceruloplasmin levels in
serum were very low. To analyze whether there is a direct
association between AT-1 expression and hepatic cerulo-
plasmin secretion, we reduced AT-1 expression in HepG2
cells by using small interfering RNA (siRNA) (Figure 5).
As a result of this treatment, we observed not only
decreased SLC33A1 mRNA levels 2 days after siRNA
transfection but also a 30% reduced secretion of cerulo-
plasmin in the medium of treated HepG2 cells compared
to controls. These results indicate that AT-1 expression
and ceruloplasmin secretion are indeed connected. To
exclude that the reduction of ceruloplasmin secretion is
a nonspecific sign of reduced protein synthesis, we
analyzed the secretion of a second protein, albumin, after
siRNA knockdown and found that it was unaltered
(Figure 5).012
Figure 3. Genomic Structure and Locali-
zation of the Mutations in the SLC33A1
Gene
The coding region is depicted in gray.
Missense mutation, arrow; nonsense
mutation, X; splice site mutation, asterisk;
insertion, down triangle; deletion, up
triangle.Discussion
In the present study, we describe a novel severe childhood
disorder leading to death in early childhood. The pheno-
type includes congenital cataracts, hearing loss, severe
developmental delay, and cerebellar hypoplasia and is
associated with low serum copper and ceruloplasmin.
Genetic analysis revealed that all patients are either homo-
zygous or compound heterozygous for mutations in the
SLC33A1 gene coding for AT-1, the ER membrane acetyl-
CoA transporter. Four of five mutations detected in the
SLC33A1 gene can be expected to severely impair the func-
tion of AT-1 by leading to a shortened or absent protein. In
patient 4, sequencing revealed a homozygous missense
mutation, p.Ala110Pro, in exon 1. Supporting its pathoge-
nicity is the fact that Ala110 is a highly conserved residue
in AT-1 and the mutation was not detected in normal
controls. Furthermore, topological prediction via the
SOSUI program shows that the mutation leads to changes
in the first and second transmembrane domains.
In 2008 it was reported that a heterozygous missense
mutation in SLC33A1, p.Ser113Arg, caused autosomal-
dominant spastic paraplegia (SPG42) in a large Chinese
family.13 In a subsequent study, 220 patients with auto-
somal-dominant spastic paraplegia were screened for
mutations in the SLC33A1 gene but no mutations were
detected.14 There is no obvious overlap between the
phenotype reported with p.Ser113Arg AT-1 mutation and
the phenotype we delineate here. Moreover, none of the
parents of the children described here who were heterozy-
gous for AT-1 mutations showed clinical signs of spastic
paraplegia. To date it therefore seems likely that SLC33A1
is not the SPG42 gene. On the other hand, in previous
reports, cataracts and optic atrophy were reported in asso-
ciation with spastic paraplegia.15–17 SLC33A1 might be
a candidate gene in these cases.
To analyze the functional consequences of the SLC33A1
mutations detected in this study, we analyzed the subcel-
lular localization of the mutant proteins. The experiments
showed a clear difference between the localization of the
AT-1 wild-type protein and the mutant proteins. However,
our experiments showed a localization of wild-type AT-1
in the cis-, medial-, and trans-Golgi and not in the ER as
described previously.18 Jonas, Pehar, and Puglielli (2010)
analyzed the subcellular localization by transfecting AT-1
that contained a Myc-His tag in CHO cells followed by
SDS-PAGE and immunoblotting after separation of intra-
cellular membranes on a Nycodenz gradient.18 To exclude
that the FLAG tag we used had influenced the localization,The Amwe repeated the experiment with a GFP tag but again
found that wild-type AT-1 was located in the Golgi. We
also considered that different cell types might display
a different localization of AT-1 and repeated the experi-
ments in HeLa and CHO cells. However, the localization
was similar in all cell types. Therefore, most probably the
conflicting results are due to the different methods used
to determine the localization of AT-1. In light of the
presumed function, it is important to further clarify the
exact subcellular localization.
AT-1 is a multiple transmembrane protein that consists
of 549 amino acids and has a mass of 60.9 kDa.12 AT-1 is
reported to be responsible for the transport of acetyl-CoA
into the lumen of the ER, serving as a substrate for acetyl-
transferases. Acetylation is an important reversible post-
translational modification of many proteins. In a recent
study, lysine acetylation sites were identified on more
than 1,700 proteins involved in various crucial cellular
processes such as splicing, chromatin remodeling, and
nuclear transport.19 It has been described that AT-1 is
essential for the transient acetylation of b-site APP cleaving
enzyme I (BACE1). Only acetylated intermediates of
BACE1 reach the Golgi complex whereas nonacetylated
intermediates are degraded in a post-ER compartment.20
The current knowledge about AT-1 does not offer an
explanation for why mutations in AT-1 lower copper and
ceruloplasmin levels. One possible explanation is that
ceruloplasmin, as a secreted glycoprotein, requires tran-
sient acetylation for proper function and the AT-1 defect
impairs this process. However, ceruloplasmin is not listed
in the mammalian ‘‘acetylome.’’19 To experimentally
assess whether AT-1 deficiency might affect ceruloplasmin
secretion, we reduced AT-1 expression in HepG2 cells with
small interfering RNA (siRNA). As a result, 30% less cerulo-
plasmin was secreted, consistent with the hypothesis that
AT-1 deficiency can indeed reduce ceruloplasmin levels.
Is AT-1 deficiency a copper metabolism disorder? Treat-
ment with copper in three of the patients did not result
in an increase in copper or ceruloplasmin levels in serum.
Clinically it was reported that the treatment did not
change the condition in two patients and resulted in an
improvement in one patient who nevertheless died at
age 4 years. The brain abnormalities we documented
(cortical and cerebellar hypoplasia and hypomyelination;
Figure 2) are also reported in patients with Menkes
disease.8 It seems possible that ATP7A, which is normally
glycosylated, also undergoes acetylation.21,22 At least six
other ATPases are acetylated.19 However, the patients we
report with AT-1 deficiency did not show other signs oferican Journal of Human Genetics 90, 61–68, January 13, 2012 65
Figure 4. Consequences of the Mutations
(A) Quantitative real-time PCR analyses revealing unchanged (P4¼ patient 4) and significantly reduced (P3¼ patient 3 and P5¼ patient 5)
SLC33A1 expression in patient fibroblasts compared to a normal control cell line. Statistical analysis was done by an unpaired Student’s t
test compared to wild-type expression in control cells. Errors are given as SEM. The p values (*p < 0.0001; **p ¼ 0.0040) were adjusted
according to Bonferroni.
(B) Western blot analysis of cell extracts (30 mg) from transiently transfected MCF-7 cells expressing the wild-type and mutated forms of
AT-1. The blot was probed with a mouse monoclonal FLAG antibody. Untransfected cells and the housekeeping gene GAPDHwere used
as controls.
(C) Subcellular localization of wild-type and mutated AT-1. The proteins were visualized by indirect immunofluorescent analysis of
MCF-7 cells transiently transfected with different FLAG-AT-1 expression constructs (red). The cells were fixed, permeabilized, and
incubated with the monoclonal antibody raised against the FLAG epitope. The wild-type AT-1 protein shows a perinuclear cytoplasmic
localization, where it colocalizes with the Golgi marker proteins Giantin and Syntaxin 6 (green, 1.A–1.C and 2.A–2.C). The protein
carrying the missense mutation Ala110Pro produced a punctate pattern and localized neither with the Golgi nor with the ER (PDI,
1.D–1.F, 2.D–2.F, 3.D–3.F). The 184-amino-acid-long truncated AT-1 protein mimicking the nonsense mutation Tyr366* was found in
the cytoplasm, where the staining pattern coincided with the ER marker PDI (3.G–3.I). The nuclei were counterstained with DAPI
and scale bars represent 10 mm.profound body copper deficiency, such as typical brittle
hair, hypopigmentation, and connective tissue laxity
as seen in Menkes disease that would be expected
with reduced ATP7A-mediated metallation of copper
enzymes.8 It seems conceivable that acetylation of ATP7A
may be required for copper absorption and delivery to
the CNS, but not for metallation of copper enzymes. There66 The American Journal of Human Genetics 90, 61–68, January 13, 2are also no signs of copper toxicity as in Wilson disease
with hepatic cirrhosis and basal ganglia degeneration.
T2* sequences available from two patients did not show
signs of iron or copper accumulation (images not shown).
Moreover, copper analyses in various organs performed in
a subset of our patients showed normal values, indicating
that the defect in AT-1 may lead to very low ceruloplasmin012
Figure 5. Downregulation of AT-1 Reduces Ceruloplasmin
Secretion in HepG2 Cells
(A) Quantitative real-time PCR analysis revealing unchanged
(ns siRNA) and statistically significant reduced (siRNA) SLC33A1
expression in HepG2 cells 2 days after transfection with and
without siRNA (control).
(B) Densitometric quantification of three independent western
blot experiments. 30 ml medium of the equal number of HepG2
cells were analyzed 2 days after transfection with SLC33A1-specific
siRNA (control). Compared to cells transfected without siRNA
(control) or nonsilencing siRNA (ns siRNA) Ceruloplasmin (black
bars), secretion was ~30% reduced but albumin (gray bars) secre-
tion unaltered in cells transfected with SLC33A1-specific siRNA
(siRNA).
Statistical analysis was done by an unpaired Student’s t test
compared to wild-type expression in control cells. Errors are
given as SEM. The p values were adjusted according to Bonferroni
(**p < 0.0001, ***p ¼ 0.0001).but not total body copper deficiency or toxicity. It is
therefore likely that the copper levels in serum are low in
patients with AT-1 defects on the basis of low cerulo-
plasmin as in aceruloplasminemia. Aceruloplasminemia
patients, however, do not become symptomatic before
adulthood and the typical symptoms (anemia, insulin-
dependent diabetes mellitus, dementia, and dystonia) do
not overlap with the symptoms seen in the patients
described here. It has already been shown that deficiency
in AT-1 has dramatic effects. Downregulation of AT-1 in
human neuroglia cells caused ER expansion as well as
autophagic cell death, and knockdown of Slc33a1 in
zebrafish resulted in curved shaped tails and defective
axon outgrowth from the spinal cord.13,18 Taken together,
the data available to date indicate that low plasma copper
and ceruloplasmin are the diagnostic hallmarks of AT-1
defects but disturbances in copper metabolism may play
only a minor role in the pathophysiology. Thus, furtherThe Aminvestigation of AT-1 function is necessary to understand
the role of AT-1 in brain metabolism and function and
for developing treatment approaches to prevent neurode-
generation and premature mortality in AT-1-deficient
patients.
In conclusion we present a novel childhood neurode-
generative disorder caused by mutations in SLC33A1.
Low copper and ceruloplasmin in serum in combination
with congenital cataracts and hearing loss seem to be the
diagnostic hallmarks but the phenotypic spectrum
remains to be explored. For further dissection of the
clinical and biochemical effects of defective acetylation
in brain development and function, generation and
investigation of AT-1-deficient cell and animal models is
necessary.Supplemental Data
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